Critical role of PAFR/YAP1 positive feedback loop in cardiac fibrosis

Tian-Yu Li1, Wei Su1, Liang-Liang Li1

  • 1Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.

Insights

Aberrant activation of cardiac fibroblasts drives fibrosis. This study reveals a platelet-activating factor (PAF) and Hippo pathway feedback loop, involving PAF receptor (PAFR) and yes-associated protein 1 (YAP1), as a key driver of cardiac fibrosis and a potential therapeutic target.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Fibrosis Research

Background:

  • Cardiac fibrosis, driven by fibroblast activation, is central to heart disease.
  • Platelet-activating factor (PAF) and the Hippo pathway are implicated in cardiovascular diseases.

Purpose of the Study:

  • To investigate the roles of PAF and the Hippo signaling pathway in cardiac fibrosis.
  • To elucidate the molecular mechanisms underlying PAF- and Hippo pathway-mediated cardiac fibrosis.

Main Methods:

  • Myocardial infarction (MI) model in mice induced by coronary artery ligation.
  • Analysis of cardiac tissue and cultured mouse cardiac fibroblasts.
  • Gene silencing using shRNA and conditional gene deletion in transgenic mice.

Main Results:

  • Increased expression of Platelet-Activating Factor Receptor (PAFR) and Yes-Associated Protein 1 (YAP1) in MI mouse hearts and Angiotensin II-treated fibroblasts.
  • PAF activates YAP1, promoting fibroblast-myofibroblast transition and collagen deposition.
  • YAP1 enhances PAFR expression, establishing a positive feedback loop.
  • Silencing PAFR or YAP1, or YAP1 deletion in fibroblasts, reduced cardiac fibrosis and improved cardiac function post-MI.

Conclusions:

  • A positive feedback loop between PAFR and YAP1 significantly contributes to cardiac fibrosis.
  • Targeting the PAFR/YAP1 pathway offers a promising therapeutic strategy for cardiac fibrosis and related heart diseases.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
81
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
62